#United States #San Diego #Class Action #MoonLake #SLK drug

MoonLake Immunotherapeutics Investors Opportunity to Lead Class Action Lawsuit

In a notable legal development for investors of MoonLake Immunotherapeutics (NASDAQ: MLTX), the well-regarded law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit, Peters v. MoonLake Immunotherapeutics, addressing substantial financial losses incurred by shareholders. This lawsuit aims to represent all purchasers or acquirers of MoonLake common stock amidst allegations of severe misleading information disseminated by the company and its executives concerning their lead product, sonelokimab (SLK).

Background of the Case

MoonLake Immunotherapeutics is a clinical-stage biotechnology company primarily focused on creating therapeutic solutions for inflammatory skin and joint diseases. The allegations within the class action suit underline significant failures in transparency from MoonLake. Central to the controversy is SLK, a drug candidate touted to be comparable or even superior in efficacy to the well-known monoclonal antibody BIMZELX, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hidradenitis suppurativa (HS).

According to the complaint, it has been revealed that SLK and BIMZELX share identical molecular targets—specifically, the inflammatory cytokines IL-17A and IL-17F. Despite MoonLake's claims about SLK's innovative Nanobody structure providing clinical advantages over traditional monoclonal antibodies like BIMZELX, evidence presented indicates that this structure failed to confer any real clinical efficacy.

The Allegations Unfold

The lawsuit specifically contends that during the relevant time frame, executives at MoonLake made a series of false and misleading statements about SLK’s ability to outperform BIMZELX. Key points raised include:
1. The assertion that SLK would deliver superior clinical outcomes compared to BIMZELX was unfounded.
2. The claims of enhanced tissue penetration due to its unique Nanobody design did not translate into effective treatment outcomes, as later results demonstrated.
3. A significant blow to MoonLake's reputation occurred on September 28, 2025, when they disclosed the results from their Phase 3 VELA study, which revealed SLK's failure to show competitive efficacy against BIMZELX. This announcement led to a staggering plummet in their stock price, nearly 90%.

The Lead Plaintiff Role Defined

Under the Private Securities Litigation Reform Act of 1995, any investor who had purchased MoonLake common stock during the class period has the right to seek the role of lead plaintiff in this class action. This lead plaintiff serves as the representative for the entire group, guiding the direction of the lawsuit. Importantly, being a lead plaintiff is based on having the most substantial financial stake and being representative of the rest of the investing cohort, rather than being necessary to qualify for potential recovery.

Investors looking to step forward as lead plaintiffs must act promptly. Applications must be submitted to the court before December 15, 2025. Interested parties are encouraged to contact the Robbins Geller law firm, reachable via their dedicated hotline or website for further information and guidance.

About Robbins Geller Rudman & Dowd LLP

A leader in securities litigation, Robbins Geller has achieved significant victories for investors, recovering over $2.5 billion in 2024 alone from securities-related class actions. With a robust team of attorneys across multiple offices, the firm remains at the forefront of protecting investors’ rights, making their involvement in the MoonLake lawsuit a critical step toward accountability and potential restitution for affected shareholders.

For more details on joining the lawsuit or seeking legal assistance, visit Robbins Geller's website. Past achievements may not guarantee future outcomes, but taking action today may provide essential avenues for recovery.

Take the step now—join the class action and safeguard your investments.